Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has announced that it is returning its territory rights to Japan-based Taiho Pharmaceutical for the development and commercialization of the oral anticancer agent S-1.
Subscribe to our email newsletter
This termination follows the announcement by Taiho Pharmaceutical of the Phase III study results which evaluated the efficacy and safety of the oral anticancer agent S-1 in a multicentric trial in patients with locally advanced gastric cancer.
The S-1 is an oral fluorouracil anticancer product that combines three pharmacological agents, tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil which inhibits dihydropyrimidine dehydrogenase enzyme activity and oteracil (potassium oxonate) a gastrointestinal side effects corrector.